Ask
Search
My library

About
Statistics
Contact
Data Protection
Accessibility
Imprint
Changelog
Frontend: v1.31.3
Backend: v1.11.4

We use cookies to provide a better user experience.

Data Protection

Adverse events (AEs) during trial period (day 0–182) by vaccination group.

Klaus Reither (259897)
Lynn Katsoulis (671835)
Trevor Beattie (671836)
Nicolene Gardiner (671837)
Nicole Lenz (671838)
Khadija Said (476408)
Elirehema Mfinanga (476407)
Christian Pohl (476404)
Katherine L. Fielding (143336)
Hannah Jeffery (671839)
Benjamin M. Kagina (671840)
Elisabeth J. Hughes (671841)
Thomas J. Scriba (76847)
Willem A. Hanekom (125097)
Søren T. Hoff (246744)
Peter Bang (671842)
Ingrid Kromann (370517)
Claudia Daubenberger (212658)
Peter Andersen (88335)
Gavin J. Churchyard (143332)

Publication date

December 2014

DOI

10.1371/journal.pone.0114602.t002

Abstract

<p>*reported as possibly related.</p><p>Adverse events (AEs) during trial period (day 0–182) by vaccination group.</p

Extracted data

Related items

Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-administration (n = 24).

Marta S. Palmeirim (4451587)
Eveline Hürlimann (217729)
Stefanie Knopp (108848)
Benjamin Speich (159922)
Vicente Belizario Jr. (5150756)
Serene A. Joseph (673044)
Michel Vaillant (39101)
Piero Olliaro (35337)
Jennifer Keiser (39606)

April 2018

<p>Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-admi...

Defining the Interval for Monitoring Potential Adverse Events Following Immunization (AEFIs) After Receipt of Live Viral Vectored Vaccines

Kochhar, Sonali
Excler, Jean-Louis
Bok, Karin
Gurwith, Marc
McNeil, Michael M.
Seligman, Stephen J.
Khuri-Bulos, Najwa
Klug, Bettina
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

September 2019

Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...

Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018)

Cross, JW
Joy, M
McGee, C
Akinyemi, O
Gatenby, P
de Lusignan, S

January 2020

BACKGROUND:Influenza contributes significantly to the burden of disease worldwide; the United Kingdo...

Subjects Experiencing at Least One Solicited Systemic Adverse Events (8-Day Follow-Up period After Vaccination, FAS, N = 632).

Richard N Greenberg (803772)
Yadira Hurley (803773)
Dinh V. Dinh (803774)
Serena Mraz (803775)
Javier Gomez Vera (803776)
Dorothea von Bredow (803777)
Alfred von Krempelhuber (724926)
Siegfried Roesch (803778)
Garth Virgin (724929)
Nathaly Arndtz-Wiedemann (724925)
Thomas Peter Meyer (803779)
Darja Schmidt (803780)
Richard Nichols (604329)
Philip Young (803781)
Paul Chaplin (366377)

October 2015

<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...

The numbers of subjects within each group reporting each related adverse event.

Sharon Sheehan (821311)
Stephanie A. Harris (429956)
Iman Satti (795581)
David A. Hokey (344045)
Veerabadran Dheenadhayalan (821312)
Lisa Stockdale (424611)
Zita-Rose Manjaly Thomas (821313)
Alice Minhinnick (821314)
Morven Wilkie (821315)
Samantha Vermaak (428177)
Joel Meyer (429955)
Matthew K. O’Shea (821316)
Maria Grazia Pau (113336)
Isabella Versteege (482832)
Macaya Douoguih (821317)
Jenny Hendriks (482831)
Jerald Sadoff (482834)
Bernard Landry (821318)
Paul Moss (345148)
Helen McShane (80704)

November 2015

<p>Local adverse events that were reported twice by individual subjects (8 adverse events) in the se...

Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.

Rajeka Lazarus (3332733)
Sarah Kelly (573743)
Matthew D. Snape (533549)
Corinne Vandermeulen (3332739)
Merryn Voysey (255058)
Karel Hoppenbrouwers (3332736)
Annick Hens (3332742)
Pierre Van Damme (147759)
Stephanie Pepin (268286)
Isabel Leroux-Roels (272410)
Geert Leroux-Roels (199739)
Andrew J. Pollard (44971)

November 2016

<p>Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination ...

Adverse events related to vaccination description and proportion of volunteers suffering any side effects.

Alberto C. Guardo (3171261)
Carmen Elena Gómez (123013)
Vicens Díaz-Brito (4532425)
Judit Pich (4532434)
Joan Albert Arnaiz (4532440)
Beatriz Perdiguero (123011)
Juan García-Arriaza (207920)
Nuria González (4532422)
Carlos O. S. Sorzano (4045436)
Laura Jiménez (372190)
José Luis Jiménez (125164)
María Ángeles Muñoz-Fernández (4532437)
José M Gatell (4532428)
José Alcamí (79441)
Mariano Esteban (50256)
Juan Carlos López Bernaldo de Quirós (4532431)
Felipe García (111854)
Montserrat Plana (300247)

October 2017

<p>Adverse events related to vaccination description and proportion of volunteers suffering any side...

Local and systemic adverse events (AEs) possibly, probably or definitely related to vaccination shown as percentage of volunteers affected.

Eoghan de Barra (676661)
Susanne H. Hodgson (634586)
Katie J. Ewer (182328)
Carly M. Bliss (391455)
Kerrie Hennigan (676662)
Ann Collins (676663)
Eleanor Berrie (182346)
Alison M. Lawrie (182358)
Sarah C. Gilbert (36739)
Alfredo Nicosia (182367)
Samuel J. McConkey (78004)
Adrian V. S. Hill (40512)

December 2014

<p>(a) Post ChAd63 CS 5×10<sup>9</sup> vp; (b) Post ChAd63 CS 5×10<sup>10</sup> vp; (c) Post MVA CS ...

Local, systemic and laboratory adverse events post immunization.

Eoghan de Barra (676661)
Susanne H. Hodgson (634586)
Katie J. Ewer (182328)
Carly M. Bliss (391455)
Kerrie Hennigan (676662)
Ann Collins (676663)
Eleanor Berrie (182346)
Alison M. Lawrie (182358)
Sarah C. Gilbert (36739)
Alfredo Nicosia (182367)
Samuel J. McConkey (78004)
Adrian V. S. Hill (40512)

December 2014

<p>Adverse events deemed possibly, probably or definitely related to vaccination are shown. ‘Other s...

Frequency of related solicited adverse events.

Zita-Rose Manjaly Thomas (821313)
Iman Satti (795581)
Julia L. Marshall (6650624)
Stephanie A. Harris (429956)
Raquel Lopez Ramon (6650627)
Ali Hamidi (6650630)
Alice Minhinnick (821314)
Michael Riste (6650633)
Lisa Stockdale (424611)
Alison M. Lawrie (182358)
Samantha Vermaak (428177)
Morven Wilkie (821315)
Henry Bettinson (6650636)
Helen McShane (80704)

April 2019

Frequency of related solicited adverse events experienced at least once; recorded at peak severity g...

Serious adverse events (SAE) reported for the period 1–5 months after the 2009 AS03-adjuvanted monovalent pandemic vaccine.

Gaston De Serres (156153)
Marie-Claude Gariépy (317009)
Brenda Coleman (317011)
Isabelle Rouleau (250665)
Shelly McNeil (317013)
Mélanie Benoît (317015)
Allison McGeer (196862)
Ardith Ambrose (317017)
Judy Needham (317018)
Chantal Bergeron (317019)
Cynthia Grenier (317020)
Kenna Sleigh (317021)
Arlene Kallos (236339)
Manale Ouakki (317022)
Najwa Ouhoummane (250661)
Grant Stiver (317023)
Louis Valiquette (186543)
Anne McCarthy (176610)
Julie Bettinger (317024)

February 2013

<p>Serious adverse events (SAE) reported for the period 1–5 months after the 2009 AS03-adjuvanted mo...

Frequency of adverse events according to the type and severity.

Dimas Tadeu Covas (6880496)
Ariane de Jesus Lopes de Abreu (14425084)
Carolina Zampirolli Dias (14425087)
Rafaela Vansan Ferreira (14425090)
Ramon Gonçalves Pereira (12358277)
Guilherme Silva Julian (8520117)

January 2023

AE: Adverse Events; 1 AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152; *AE reported as ...

Adverse Events (AE).

Joseph J. Grudzinski (662493)
Benjamin Titz (662494)
Kevin Kozak (662495)
William Clarke (433138)
Ernest Allen (662496)
LisaAnn Trembath (662497)
Michael Stabin (662498)
John Marshall (39501)
Steve Y. Cho (662499)
Terence Z. Wong (662500)
Joanne Mortimer (662501)
Jamey P. Weichert (400808)

November 2014

<p>The AE experienced during the study are listed.</p><p><sup>*</sup>Frequency: 1 = Intermittent, 2...

Observed laboratory adverse events for all dose escalation groups.

Kwadwo A. Koram (172174)
Bright Adu (133241)
Josephine Ocran (324669)
Yaa S. Karikari (3127095)
Susan Adu-Amankwah (3127104)
Michael Ntiri (3127098)
Benjamin Abuaku (3127101)
Daniel Dodoo (40242)
Ben Gyan (134411)
Karl C. Kronmann (317416)
Francis Nkrumah (78754)

September 2016

<p><b>Panel A</b> is for screening prior to enrolment; <b>Panels B</b> and <b>C</b> are for vaccinat...

Adverse events reported during 28 days following Doses 1 and 2 of trivalent seasonal influenza vaccine: number of adverse events (number of vaccine-attributable adverse events).

Delia Bethell (221145)
David Saunders (221160)
Anan Jongkaewwattana (394525)
Jarin Kramyu (394526)
Arunee Thitithayanont (394527)
Suwimon Wiboon-ut (394528)
Kosol Yongvanitchit (394529)
Amporn Limsalakpetch (394530)
Utaiwan Kum-Arb (394531)
Nichapat Uthaimongkol (394532)
Jean Michel Garcia (394533)
Ans E. Timmermans (394534)
Malik Peiris (268565)
Stephen Thomas (17628)
Anneke Engering (394535)
Richard G. Jarman (150957)
Duangrat Mongkolsirichaikul (394536)
Carl Mason (274588)
Nuanpan Khemnu (394537)
Stuart D. Tyner (224021)
Mark M. Fukuda (221184)
Douglas S. Walsh (257138)
Sathit Pichyangkul (394538)

March 2013

<p>LAIV = live attenuated influenza vaccine; IIV = inactivated influenza vaccination; AE = adverse e...

Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-administration (n = 24).

Marta S. Palmeirim (4451587)
Eveline Hürlimann (217729)
Stefanie Knopp (108848)
Benjamin Speich (159922)
Vicente Belizario Jr. (5150756)
Serene A. Joseph (673044)
Michel Vaillant (39101)
Piero Olliaro (35337)
Jennifer Keiser (39606)

April 2018

<p>Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-admi...

Defining the Interval for Monitoring Potential Adverse Events Following Immunization (AEFIs) After Receipt of Live Viral Vectored Vaccines

Kochhar, Sonali
Excler, Jean-Louis
Bok, Karin
Gurwith, Marc
McNeil, Michael M.
Seligman, Stephen J.
Khuri-Bulos, Najwa
Klug, Bettina
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

September 2019

Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...

Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018)

Cross, JW
Joy, M
McGee, C
Akinyemi, O
Gatenby, P
de Lusignan, S

January 2020

BACKGROUND:Influenza contributes significantly to the burden of disease worldwide; the United Kingdo...

Subjects Experiencing at Least One Solicited Systemic Adverse Events (8-Day Follow-Up period After Vaccination, FAS, N = 632).

Richard N Greenberg (803772)
Yadira Hurley (803773)
Dinh V. Dinh (803774)
Serena Mraz (803775)
Javier Gomez Vera (803776)
Dorothea von Bredow (803777)
Alfred von Krempelhuber (724926)
Siegfried Roesch (803778)
Garth Virgin (724929)
Nathaly Arndtz-Wiedemann (724925)
Thomas Peter Meyer (803779)
Darja Schmidt (803780)
Richard Nichols (604329)
Philip Young (803781)
Paul Chaplin (366377)

October 2015

<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...

The numbers of subjects within each group reporting each related adverse event.

Sharon Sheehan (821311)
Stephanie A. Harris (429956)
Iman Satti (795581)
David A. Hokey (344045)
Veerabadran Dheenadhayalan (821312)
Lisa Stockdale (424611)
Zita-Rose Manjaly Thomas (821313)
Alice Minhinnick (821314)
Morven Wilkie (821315)
Samantha Vermaak (428177)
Joel Meyer (429955)
Matthew K. O’Shea (821316)
Maria Grazia Pau (113336)
Isabella Versteege (482832)
Macaya Douoguih (821317)
Jenny Hendriks (482831)
Jerald Sadoff (482834)
Bernard Landry (821318)
Paul Moss (345148)
Helen McShane (80704)

November 2015

<p>Local adverse events that were reported twice by individual subjects (8 adverse events) in the se...

Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.

Rajeka Lazarus (3332733)
Sarah Kelly (573743)
Matthew D. Snape (533549)
Corinne Vandermeulen (3332739)
Merryn Voysey (255058)
Karel Hoppenbrouwers (3332736)
Annick Hens (3332742)
Pierre Van Damme (147759)
Stephanie Pepin (268286)
Isabel Leroux-Roels (272410)
Geert Leroux-Roels (199739)
Andrew J. Pollard (44971)

November 2016

<p>Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination ...

Adverse events related to vaccination description and proportion of volunteers suffering any side effects.

Alberto C. Guardo (3171261)
Carmen Elena Gómez (123013)
Vicens Díaz-Brito (4532425)
Judit Pich (4532434)
Joan Albert Arnaiz (4532440)
Beatriz Perdiguero (123011)
Juan García-Arriaza (207920)
Nuria González (4532422)
Carlos O. S. Sorzano (4045436)
Laura Jiménez (372190)
José Luis Jiménez (125164)
María Ángeles Muñoz-Fernández (4532437)
José M Gatell (4532428)
José Alcamí (79441)
Mariano Esteban (50256)
Juan Carlos López Bernaldo de Quirós (4532431)
Felipe García (111854)
Montserrat Plana (300247)

October 2017

<p>Adverse events related to vaccination description and proportion of volunteers suffering any side...

Local and systemic adverse events (AEs) possibly, probably or definitely related to vaccination shown as percentage of volunteers affected.

Eoghan de Barra (676661)
Susanne H. Hodgson (634586)
Katie J. Ewer (182328)
Carly M. Bliss (391455)
Kerrie Hennigan (676662)
Ann Collins (676663)
Eleanor Berrie (182346)
Alison M. Lawrie (182358)
Sarah C. Gilbert (36739)
Alfredo Nicosia (182367)
Samuel J. McConkey (78004)
Adrian V. S. Hill (40512)

December 2014

<p>(a) Post ChAd63 CS 5×10<sup>9</sup> vp; (b) Post ChAd63 CS 5×10<sup>10</sup> vp; (c) Post MVA CS ...

Local, systemic and laboratory adverse events post immunization.

Eoghan de Barra (676661)
Susanne H. Hodgson (634586)
Katie J. Ewer (182328)
Carly M. Bliss (391455)
Kerrie Hennigan (676662)
Ann Collins (676663)
Eleanor Berrie (182346)
Alison M. Lawrie (182358)
Sarah C. Gilbert (36739)
Alfredo Nicosia (182367)
Samuel J. McConkey (78004)
Adrian V. S. Hill (40512)

December 2014

<p>Adverse events deemed possibly, probably or definitely related to vaccination are shown. ‘Other s...

Frequency of related solicited adverse events.

Zita-Rose Manjaly Thomas (821313)
Iman Satti (795581)
Julia L. Marshall (6650624)
Stephanie A. Harris (429956)
Raquel Lopez Ramon (6650627)
Ali Hamidi (6650630)
Alice Minhinnick (821314)
Michael Riste (6650633)
Lisa Stockdale (424611)
Alison M. Lawrie (182358)
Samantha Vermaak (428177)
Morven Wilkie (821315)
Henry Bettinson (6650636)
Helen McShane (80704)

April 2019

Frequency of related solicited adverse events experienced at least once; recorded at peak severity g...

Serious adverse events (SAE) reported for the period 1–5 months after the 2009 AS03-adjuvanted monovalent pandemic vaccine.

Gaston De Serres (156153)
Marie-Claude Gariépy (317009)
Brenda Coleman (317011)
Isabelle Rouleau (250665)
Shelly McNeil (317013)
Mélanie Benoît (317015)
Allison McGeer (196862)
Ardith Ambrose (317017)
Judy Needham (317018)
Chantal Bergeron (317019)
Cynthia Grenier (317020)
Kenna Sleigh (317021)
Arlene Kallos (236339)
Manale Ouakki (317022)
Najwa Ouhoummane (250661)
Grant Stiver (317023)
Louis Valiquette (186543)
Anne McCarthy (176610)
Julie Bettinger (317024)

February 2013

<p>Serious adverse events (SAE) reported for the period 1–5 months after the 2009 AS03-adjuvanted mo...

Frequency of adverse events according to the type and severity.

Dimas Tadeu Covas (6880496)
Ariane de Jesus Lopes de Abreu (14425084)
Carolina Zampirolli Dias (14425087)
Rafaela Vansan Ferreira (14425090)
Ramon Gonçalves Pereira (12358277)
Guilherme Silva Julian (8520117)

January 2023

AE: Adverse Events; 1 AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152; *AE reported as ...

Adverse Events (AE).

Joseph J. Grudzinski (662493)
Benjamin Titz (662494)
Kevin Kozak (662495)
William Clarke (433138)
Ernest Allen (662496)
LisaAnn Trembath (662497)
Michael Stabin (662498)
John Marshall (39501)
Steve Y. Cho (662499)
Terence Z. Wong (662500)
Joanne Mortimer (662501)
Jamey P. Weichert (400808)

November 2014

<p>The AE experienced during the study are listed.</p><p><sup>*</sup>Frequency: 1 = Intermittent, 2...

Observed laboratory adverse events for all dose escalation groups.

Kwadwo A. Koram (172174)
Bright Adu (133241)
Josephine Ocran (324669)
Yaa S. Karikari (3127095)
Susan Adu-Amankwah (3127104)
Michael Ntiri (3127098)
Benjamin Abuaku (3127101)
Daniel Dodoo (40242)
Ben Gyan (134411)
Karl C. Kronmann (317416)
Francis Nkrumah (78754)

September 2016

<p><b>Panel A</b> is for screening prior to enrolment; <b>Panels B</b> and <b>C</b> are for vaccinat...

Adverse events reported during 28 days following Doses 1 and 2 of trivalent seasonal influenza vaccine: number of adverse events (number of vaccine-attributable adverse events).

Delia Bethell (221145)
David Saunders (221160)
Anan Jongkaewwattana (394525)
Jarin Kramyu (394526)
Arunee Thitithayanont (394527)
Suwimon Wiboon-ut (394528)
Kosol Yongvanitchit (394529)
Amporn Limsalakpetch (394530)
Utaiwan Kum-Arb (394531)
Nichapat Uthaimongkol (394532)
Jean Michel Garcia (394533)
Ans E. Timmermans (394534)
Malik Peiris (268565)
Stephen Thomas (17628)
Anneke Engering (394535)
Richard G. Jarman (150957)
Duangrat Mongkolsirichaikul (394536)
Carl Mason (274588)
Nuanpan Khemnu (394537)
Stuart D. Tyner (224021)
Mark M. Fukuda (221184)
Douglas S. Walsh (257138)
Sathit Pichyangkul (394538)

March 2013

<p>LAIV = live attenuated influenza vaccine; IIV = inactivated influenza vaccination; AE = adverse e...

Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-administration (n = 24).

Marta S. Palmeirim (4451587)
Eveline Hürlimann (217729)
Stefanie Knopp (108848)
Benjamin Speich (159922)
Vicente Belizario Jr. (5150756)
Serene A. Joseph (673044)
Michel Vaillant (39101)
Piero Olliaro (35337)
Jennifer Keiser (39606)

April 2018

<p>Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-admi...

Defining the Interval for Monitoring Potential Adverse Events Following Immunization (AEFIs) After Receipt of Live Viral Vectored Vaccines

Kochhar, Sonali
Excler, Jean-Louis
Bok, Karin
Gurwith, Marc
McNeil, Michael M.
Seligman, Stephen J.
Khuri-Bulos, Najwa
Klug, Bettina
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

September 2019

Live viral vectors that express heterologous antigens of the target pathogen are being investigated ...

Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018)

Cross, JW
Joy, M
McGee, C
Akinyemi, O
Gatenby, P
de Lusignan, S

January 2020

BACKGROUND:Influenza contributes significantly to the burden of disease worldwide; the United Kingdo...